PT Kalbe Farma Tbk · IDX:KLBF
PT Kalbe Farma Tbk — Morgan Stanley Asia Pacific Summit 2012
35 slides from PT Kalbe Farma Tbk's conference presentation, November 2012
Slide 1: Morgan Stanley Asia Pacific Summit 2012
Morgan Stanley Asia Pacific Summit 2012 November 2012 Healthy, Tasty Excellence in Execution
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 30 September 2012 unaudited results of the Company. The information co
Slide 3: Investment Highlights
Investment Highlights Largest Publicly-Listed 46-year old pharmaceutical company with long track record of profitable growth Pharmaceutical Company in The largest publicly-listed pharmaceutical company in Southeast Asia with over US$5 billion Southeast Asia market cap Large target population o
Slide 4: Corporate Overview
SECTION 1 Corporate Overview 4 Excellence in Execution
Slide 5: Corporate Overview
Corporate Overview Largest Publicly-Listed Pharmaceuticals Company in Southeast Asia • Established in 1966 and headquartered in Jakarta • A public company since 1991 and listed in the Indonesia Stock Exchange • The largest publicly-listed pharmaceuticals company in Southeast Asia • Sales breakdown b
Slide 6: Corporate Strategy
Corporate Strategy Kalbe Has a Long Track record of Sustainable Growth Inception and Entrepreneurial Enhanced Focus and Consolidation Regionalization Driven Expansion 1996–2005 2006–2015 1966–1995 2012: 2010: ♦ Generic production 1981: 1995: Disposed of Kageo Igar Jaya facility comes on stream Spi
Slide 7: Business Environment
SECTION 2 Business Environment 7 Excellence in Execution
Slide 8: Indonesia Pharma Market Growth
Indonesia Pharma Market Growth Source: IMS Health Market Prognosis, October 2011 8 Excellence in Execution
Slide 9: Strong Economic Growth
Strong Economic Growth GDP per capita (US$) GDP 15,000 GDP 10,000 20,603 20,256 20,525 16,107 14,978 15,338 13,024 12,944 GDP 5,000 10,985 10,277 7,615 6,591 5,260 5,546 4,630 3,374 Poland Brazil Russia Mexico Turkey China Thailand Indonesia 2011 2015 GDP per capita to reach Source: Business Monitor
Slide 10: Attractive Demographics Profile
Attractive Demographics Profile Expansion of Middle Class Segment with Rising Disposable Income 10 Excellence in Execution
Slide 11: Low but rising healthcare expenditure
Low but rising healthcare Low pharmaceuticals spending due expenditure to low penetration Healthcare Expenditure/GDP 2010 (%) Pharmaceuticals Spending 2010 % 4.8% 1.2 (US Dollar) % 4.1% 119.6 3.8% 1 % 3.5% % 3.3% 0.8 % % 2.1% 0.6 % 58.6 0.4 50.3 % % 29.9 0.2 % 17.4 11.4 % 0 Malaysia Thailand Philipp
Slide 12: Universal Coverage Implementation
Universal Coverage Implementation Universal Coverage – a Driving Force for Increasing Health Expenditure • Law on National Social Security System has been passed since 2004, but implementation regulation on Social Security Provider Body (BPJS) has just been passed in October 2011. The Government an
Slide 13: Business Overview
SECTION 3 Business Overview 13 Excellence in Execution
Slide 14: Prescription Pharmaceuticals Division
Prescription Pharmaceuticals Division Leading the Market with Comprehensive Product Range Total Market (ITMA) Sales Contribution By YTD 12 2011 Product Categories YTD 09 2012 b KALBE a 6% c d e GROUP 8% 4% 4% 4% 12% f Licensed 4% Products 32% Branded Generics Unbranded 58% Generics OTHERS 10% 58% To
Slide 15: Prescription Pharmaceuticals Division: Gearing-up Towards Universal Coverage
Prescription Pharmaceuticals Division Gearing-up Towards the Universal Coverage • Focus on unbranded generics: • Dedicated for unbranded generic drugs’ tablet production line to increase production efficiency and scale. • Strategic raw material sourcing • Distribution network expansion: • Building m
Slide 16: Consumer Health Division: Care for Family
Consumer Health Division Care for Family Health for a Productive Life 16 Excellence in Execution
Slide 17: Consumer Health Division: Strong Brand Equity
Consumer Health Division Strong Brand Equity with Leading Market Position Market share of Kalbe’s brands YTD December 2011 Therapeutic Class Kalbe’s Products Market Share by Volume Antacid Promag, Waisan 77.4%* Anti Diarrhea Neo Entrostop 44.8%** Cough Remedies Komix, Woods, Mextril, Mixadin 39.1% C
Slide 18: Consumer Health Division: Leading Market Position
Consumer Health Division Leading Market Position OTC Energy Drink YTD 12 2011 YTD 12 2011 (Unit) b c d Others a 8% 8% 5% d 8% e c 6% 8% f a 4% 7% KALBE 4% 42% GROUP 13% b OTHERS 13% Extra Joss 50% 24% Total Market = Rp 18.0Tn Total Market (in volume) = 2,371Mn Source : IMS Health ITMA OTC YTD 12 201
Slide 19: Consumer Health Division: Innovative New Products
Consumer Health Division Innovative New Products with Health Benefits Hydro Coco An isotonic drink made of pure coconut water. Tipco Fruit & Vegetable Juice A healthy drink made of fruits and vegetables Original Love Juice & Pomerama Fresh bottled fruit juice made of quality fruits available in oran
Slide 20: Nutritionals Division: Complete Range
Nutritionals Division Complete Range of Nutritional Products • Catered to expecting & lactating mothers, babies, toddlers, children, tweens and adults. Expecting Lactating Baby Toddler Kid Tween Teen 25+ 35+ Clinical 20 Excellence in Execution
Slide 21: Nutritionals Division: Gaining Market Shares
Nutritionals Division Gaining Market Shares Against Multinational Competitors Powder Milk Market Share YTD 12 2011 Market Share of Kalbe Nutritionals Products in its Category YTD December 2011 h i g f 3% 3% 2% Others Kalbe’s Products Market Share e 2% 3% a 6% 31% Diabetasol 79.5% d Milna 63.5% 9% Pr
Slide 22: Nutritionals Division: Launching of Products
Nutritionals Division Launching of Nutritional Products Fitbar A healthy snack bar made of oats and cereals that comes in 2 flavors, fruits and nuts, with only 110 calories per bar, Zero Cholesterol and Zero Trans Fat, enriched with Calcium, Vitamins A, B12 and C. KidZee and Zee Powder milk for kids
Slide 23: Nutritionals Division: Multi Channel Touch Points
Nutritionals Division Multi Channel Customer Touch Points Kalbe e-store - the 1st Online Nutrition Store in Indonesia We increase brand activation and direct-to-customer activities to build closer relationships with our customers. Excellence in Execution 23
Slide 24: Distribution & Logistics: Most Extensive Network
Distribution & Logistics Division The Most Extensive Distribution Network RDC Branches Cities 2 65 47 24 Excellence in Execution
Slide 25: Distribution & Logistics: Major Third Party Principals
Distribution & Logistics Division Major Third Party Principals by Category Fine Chemical Raw Materials 7% 3rd Party Principals 4% 23% Kalbe Group 66% Distribution & Logistics and Health Services 25 Excellence in Execution
Slide 26: Distribution & Logistics: Medical Devices Growth Driver
Distribution & Logistics Division Medical Devices, a New Growth Driver Medical Devices is an area of potential growth, especially in the implementation of National Healthcare Insurance System where demand for medical devices is projected to grow further. Net Sales (in Rp Bn) Major Principals Medical
Slide 27: New Retail Health Service: Mitrasana Clinic
Distribution & Logistics Strategies New Retail Health Service : Mitrasana Clinic • Opening of Mitrasana Clinics as a one-stop service with 4-in- 1 concept, including family doctor, pharmacy, laboratory, and convenient store. • A 100% owned subsidiary of EPMT. • Operational excellence in several area
Slide 28: Regional Expansion
Regional Expansion Expand and deepen market penetration in ASEAN 28 Excellence in Execution
Slide 29: Marketing and Sales Infrastructure
Marketing and Sales Infrastructure The Largest Sales Force for Pharma and Consumer Health in Indonesia Prescription Distribution & Consumer Health Nutritionals Pharmaceuticals Logistics • Over 2,000 sales & • Over 2,300 medical • Approximately 1,000 • Over 1,000 marketing marketing personnel represe
Slide 30: Manufacturing Infrastructure
Manufacturing Infrastructure Operates 11 GMP Facilities Complying with International Standards Products Building Area Facility Production Lines Licenses Certification Manufactured (m2) 9 lines of Non Beta Lactam Products ISO 9001, ISO 14001, Kalbe Farma 448 42,684 Astellas (tablet, capsule, cream, l
Slide 31: Financial Overview
SECTION 4 Financial Overview 31 Excellence in Execution
Slide 32: Financial Overview
Financial Overview Sustainable Revenue and Profitability Growth Revenues Operating Income Net Income 12,000 2,500 1,600 10,000 1,400 2,000 1,200 (IDR Bn) (IDR Bn) (IDR Bn) 8,000 1,500 1,000 6,000 800 1,000 600 4,000 500 400 2,000 200 - - - 2009 2010 2011 YTD 09 2009 2010 2011 YTD 09 2009 2010 2011 Y
Slide 33: Solid Financial Position
Solid Financial Position Rp 1.2 Trillion of Net Cash Position Total Debt and Gearing Ratio Cash & Net Cash Balance 2,291 450 11.2% 12.0% 2,151 400 1,902 10.0% 1,877 350 7.9% 1,562 300 8.0% 1,373 1,322 1,257 250 1,223 6.0% 200 405 917 340 150 4.0% 2.3% 100 1.8% 141 2.0% 50 0.5% 116 25 0 0.0% FY 2008
Slide 34: Innovation for a Better Life
Innovation for a Better Life 34 Excellence in Execution
Slide 35: Thank You
THANK YOU For further information: PT Kalbe Farma Tbk. Jalan Let.Jend. Suprapto Kav. 4 Jakarta 10510, Indonesia Tel. : 62-21-42873888 Fax. : 62-21-42873678 Email : vidjongtius@kalbe.co.id jhandajani@kalbe.co.id investor.relations@kalbe.co.id Website : www.kalbe.co.id 35 Excellence in Execution
PT Kalbe Farma — Morgan Stanley Asia Pacific Summit 2012 on 6ix